DA-EPOCH-R for Post-Transplant Lymphoproliferative Disorders (PTLD).

DA-EPOCH-R for Post-Transplant Lymphoproliferative Disorders (PTLD).

Eur J Haematol. 2017 May 16;:

Authors: DeStefano CB, Malkovska V, Rafei H, Shenoy A, Fitzpatrick K, Aggarwal A, Catlett JP

Abstract
Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous and potentially fatal group of neoplasms arising in an immunodeficient environment in the background of viral antigenic stimulation. PTLD is rare, with an incidence in solid organ transplant recipients typically less than 20% [1]. For aggressive, monomorphic cases, current guidelines recommend reduced immunosuppression in addition to chemoimmunotherapy, which generally consists of R-CHOP [1]. Nevertheless, prognosis is poor with 5-year overall survival (OS) rates of only 40-60% [1]. Thus improved treatment approaches are needed. This article is protected by copyright. All rights reserved.

PMID: 28509395 [PubMed - as supplied by publisher]

http://ift.tt/2pVwigI